2005
DOI: 10.1016/s0960-9776(05)80107-9
|View full text |Cite
|
Sign up to set email alerts
|

P70 The ADEBAR-trial — participation in a randomized phase III study (evaluating the role of adjuvant docetaxel in high-risk breast cancer patients) improves treatment strategies and individual patient care in recruiting centers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
10
0

Year Published

2013
2013
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(10 citation statements)
references
References 0 publications
0
10
0
Order By: Relevance
“…Another analysis of breast cancer showed that participation in a clinical trial improved guideline-directed care, treatment of higher-risk patients, and patient education and engagement in their care. 6 There are several potential factors that may contribute to these findings, both in the previous studies described as well as in the care of patients with CLI. Trial participation can reinforce guidelinedirected therapy and improve medical optimization through protocols, with the hope of continuing these practices after the trial ends.…”
Section: Discussionmentioning
confidence: 93%
See 4 more Smart Citations
“…Another analysis of breast cancer showed that participation in a clinical trial improved guideline-directed care, treatment of higher-risk patients, and patient education and engagement in their care. 6 There are several potential factors that may contribute to these findings, both in the previous studies described as well as in the care of patients with CLI. Trial participation can reinforce guidelinedirected therapy and improve medical optimization through protocols, with the hope of continuing these practices after the trial ends.…”
Section: Discussionmentioning
confidence: 93%
“…Trial participation can reinforce guidelinedirected therapy and improve medical optimization through protocols, with the hope of continuing these practices after the trial ends. [4][5][6][7] For CLI, optimal medical therapy, specifically with antiplatelet agents and statins, have been shown to improve patency of interventions and limb salvage. [10][11][12] Follow-up is often a problem when patients are treated for CLI.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations